Skin Permeation of Rosiglitazone from Transdermal Matrix Patches - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Skin Permeation of Rosiglitazone from Transdermal Matrix Patches
The authors demonstrate that sustained-release delivery can help avoid the risk of sudden higher-blood concentration of a drug to avoid toxicity.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 56-72

References

1. E. Bonora et al., Diabetes 47 (10), 1643–1649 (1998).

2. S.M. Haffner et al., Diabetes 46 (1) , 63–69 (1997).

3. L.A. Werner and T.M. Travaglini, Pharmacotherapy 21 (9) , 1082–1099 (2001).

4. S.E. Nissen and K. Wolski, N. Engl. J. Med. 356 (24), 2457–2471 (2007).

5. S. Singh, Y.K. Loke, and C.D. Furberg, JAMA 298 (10), 1189–1195 (2007).

6. M. Hanefeld, Nat. Clin. Pract. Cardiovasc. Med. 4 (12), 648–649 (2007).

7. S.J. Baldwin, S.E. Clarke, and R.J. Chenery, Brit. J. Clin. Pharmacol. 48 (3), 424–432, (1999).

8. P.J. Cox et al., Drug Metab. Dispos. 28 (7), 772–780 (2000).

9. M. Segal, FDA Consum. 25 (8), 15–17 (1991).

10. P.P. Sarpotdar, J.L. Gaskill, and R.P. Giannini, J. Pharm. Sci. 75 (1), 26–28 (1986).

11. S. Proniuk , S.E. Dixon, and J. Blanchard, Pharm. Dev. Technol. 6 (3), 469–476 (2001).

12. B. Mukherjee et al., Eur J. Pharm. Biopharm. 59 (3), 475–483 (2005).

13. J. Fang et al., Biol. Pharm. Bull. 23 (11), 1357–1362 (2000).

14. B. Mukherjee et al., Pharm. Technol. 30 (3) , 146–163 (2006).

15. B. Mukherjee et al., J. Appl. Res. 5 (1), 96–108 (2005).

16. Y.W. Chien and K.H. Valia, Drug Dev. Ind. Pharm. 10 (4), 575–599 (1984).

17. N.S. Thomas and R. Panchagnula, Eur. J. Pharm. Sci. 18 (1), 71–79 2003.

18. B.L. Kolte et al., J. Chromatogr. B. Analyt. Technol. Biomed Life Sci. 788 (1), 37–44 (2003).

19. Y.W Chien, "Transdermal Therapeutic Systems," in Controlled Drug Delivery: Fundmentals and Applications, J.R. Robinson and V.H.L. Lee, Eds. (Marcel Dekker, New York, 2nd ed., 1987), pp. 524–552.

20. A.V. Pocius, "Adhesives," in Kirk-Othmer Encyclopedia of Chemical Technology, M. Howe-Grants, Ed. (Wiley-Interscience, New York, 1991), pp. 445–466.

21. A. Marini et al., J. Therm. Anal. Calorim. 73 (2), 547–561 (2003).

22. P. Arora and B. Mukherjee, J. Pharm. Sci. 91 (9), 2076–2089 (2002).

23. P.M. Satturwar, S.V. Fulzele, and A.K. Dorle, AAPS PharmSciTech. 6 (4), 49-54 (2005).

24. N.M Price et al., Clin. Pharmacol. Ther. 29 (3) , 414–420 (1981).

25. R.A. Codario, "Oral Agents for Type 2 Diabetes," in Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome: The Primary Guide to Diagnosis and Management, R.A. Codario, Ed. (Humana Press, Totowa, NJ, 2005), pp. 75–92.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here